149.8K XNAS Volume
XNAS 19 Mar, 2025 1:04 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 192,000 | 192,000 | - | - | Restricted Stock Unit | |
| Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 288,000 | 288,000 | - | - | Stock Option (Right to Buy) | |
| Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 53,000 | 53,000 | - | - | Restricted Stock Unit | |
| Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 79,000 | 79,000 | - | - | Stock Option (Right to Buy) | |
| Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 53,000 | 53,000 | - | - | Restricted Stock Unit | |
| Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 79,000 | 79,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 47,666 | 71,428 (0%) | 0% | 0 | Common Stock | |
| Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 23,885 | 47,543 (0%) | 0% | 14.9 | 356,462 | Common Stock |
| Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 66,666 | 114,209 (0%) | 0% | 0 | Common Stock | |
| Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 33,406 | 80,803 (0%) | 0% | 14.9 | 498,554 | Common Stock |
| Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 47,666 | 47,668 | - | - | Restricted Stock Unit | |
| Kenneth Galbraith | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 66,666 | 133,334 | - | - | Restricted Stock Unit | |
| Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Jeffrey T.L. Smith | EVP & Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 11,110 | 8,890 (0%) | 0% | 14.9 | 165,807 | Common Stock |
| Jeffrey T.L. Smith | EVP & Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 40,000 | - | - | Restricted Stock Unit | |
| Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 17,166 | 24,533 (0%) | 0% | 0 | Common Stock | |
| Paul Andrew Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 9,792 | 14,741 (0%) | 0% | 14.9 | 146,137 | Common Stock |
| Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 34,741 (0%) | 0% | 0 | Common Stock | |
| Paul Andrew Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 14.92 per share. | 06 Jan 2025 | 11,408 | 23,333 (0%) | 0% | 14.9 | 170,254 | Common Stock |
| Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 17,166 | 17,168 | - | - | Restricted Stock Unit | |
| Paul Andrew Moore | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jan 2025 | 20,000 | 40,000 | - | - | Restricted Stock Unit | |
| Gallagher Neil | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Derek J. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Carlos Campoy E. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Neu M. Kelvin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Alessandra Cesano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Cox Troy M. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Davidson Nancy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Dec 2024 | 31,000 | 31,000 | - | - | Stock Option (Right to Buy) | |
| Leone D Patterson | EVP, Chief Bus & Fin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 360,000 | 360,000 | - | - | Stock Option (Right to Buy) | |
| Neil Gallagher | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 74,000 | 74,000 | - | - | Stock Option (Right to Buy) | |
| Cesano Alessandra | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 74,000 | 74,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 300,000 | 300,000 | - | - | Stock Option (Right to Buy) | |
| Andrew Moore Paul | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,166 | 17,166 (0%) | 0% | 0 | Common Stock | |
| Christopher Astle | SVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 05 Jan 2024 | 4,563 | 7,934 (0%) | 0% | 10.7 | 48,606 | Common Stock |
| Christopher Astle | SVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 05 Jan 2024 | 1,431 | 6,503 (0%) | 0% | 11.2 | 16,050 | Common Stock |
| Moore Paul Andrew | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Astle Christopher | SVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 10,500 | 12,497 (0%) | 0% | 0 | Common Stock | |
| Moore Andrew Paul | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Moore Paul Andrew | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 05 Jan 2024 | 2,339 | 7,367 (0%) | 0% | 11.2 | 26,233 | Common Stock |
| Astle Christopher | SVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Galbraith Kenneth | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 05 Jan 2024 | 18,198 | 29,468 (0%) | 0% | 10.7 | 193,849 | Common Stock |
| Andrew Paul Moore | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 10.65 per share. | 05 Jan 2024 | 7,460 | 9,706 (0%) | 0% | 10.7 | 79,465 | Common Stock |
| Astle Christopher | SVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 10,500 | 21,000 | - | - | Restricted Stock Unit | |
| Galbraith Kenneth | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 47,666 | 47,666 (0%) | 0% | 0 | Common Stock | |
| Moore Paul Andrew | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 17,166 | 34,334 | - | - | Restricted Stock Unit | |
| Christopher Astle | SVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 30,000 | 30,000 | - | - | Restricted Stock Unit | |
| Kenneth Galbraith | Director, Chair & CEO | Sale of securities on an exchange or to another person at price $ 11.22 per share. | 05 Jan 2024 | 5,706 | 23,762 (0%) | 0% | 11.2 | 63,996 | Common Stock |
| Galbraith Kenneth | Director, Chair & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 47,666 | 95,334 | - | - | Restricted Stock Unit | |
| Galbraith Kenneth | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 200,000 | 200,000 | - | - | Restricted Stock Unit | |
| Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 60,000 | 60,000 | - | - | Restricted Stock Unit | |
| Jeffrey T.L. Smith | EVP & Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Astle | SVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 1,550 | 2,883 (0%) | 0% | 0 | Common Stock | |
| Christopher Astle | SVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.13 per share. | 11 Dec 2023 | 886 | 1,997 (0%) | 0% | 9.1 | 8,089 | Common Stock |
| Christopher Astle | SVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 1,550 | 0 | - | - | Restricted Stock Unit | |
| Neu M. Kelvin | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Campoy E. Carlos | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Hillan J. Kenneth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Renton Hollings C. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Nancy Davidson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 74,000 | 74,000 | - | - | Stock Option (Right to Buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| J. Miller Derek | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| M. Troy Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Dec 2023 | 37,000 | 37,000 | - | - | Stock Option (Right to Buy) | |
| Derek Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2023 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,500 | 17,301 (0%) | 0% | 0 | Common Stock | |
| Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,708 | 20,009 (0%) | 0% | 0 | Common Stock | |
| Neil Klompas | President & COO | Sale of securities on an exchange or to another person at price $ 7.83 per share. | 10 Mar 2023 | 2,977 | 17,032 (0%) | 0% | 7.8 | 23,298 | Common Stock |
| Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,500 | 0 | - | - | Restricted Stock Unit | |
| Neil Klompas | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2023 | 2,708 | 2,709 | - | - | Restricted Stock Unit | |
| Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 143,000 | 143,000 | - | - | Restricted Stock Unit | |
| Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 215,000 | 215,000 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 87,500 | 87,500 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 58,500 | 58,500 | - | - | Restricted Stock Unit | |
| Christopher Astle | SVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 31,500 | 31,500 | - | - | Restricted Stock Unit | |
| Christopher Astle | SVP & Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 47,000 | 47,000 | - | - | Stock Option (Right to Buy) | |
| Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 77,500 | 77,500 | - | - | Stock Option (Right to Buy) | |
| Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2023 | 51,500 | 51,500 | - | - | Restricted Stock Unit | |
| Kenneth Galbraith | Director, Chair & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Dec 2022 | 100,000 | 100,000 | - | - | Restricted Stock Unit | |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Lota S. Zoth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Kelvin M. Neu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Natalie Sacks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Troy Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Christopher Astle | SVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 1,550 | 2,220 (0%) | 0% | 0 | Common Stock | |
| Christopher Astle | SVP & Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 12 Dec 2022 | 887 | 1,333 (0%) | 0% | 6.0 | 5,331 | Common Stock |
| Christopher Astle | SVP & Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2022 | 1,550 | 1,550 | - | - | Restricted Stock Unit | |
| Neil Josephson | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 5,885 | 16,924 (0%) | 0% | 0 | Common Stock | |
| Neil Josephson | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 8.10 per share. | 10 Nov 2022 | 2,475 | 14,449 (0%) | 0% | 8.1 | 20,045 | Common Stock |
| Neil Josephson | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 5,885 | 11,772 | - | - | Restricted Stock Unit | |
| Paul Andrew Moore | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2022 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 4.51 per share. | 05 Jul 2022 | 1,525 | 14,801 (0%) | 0% | 4.5 | 6,878 | Common Shares |
| Neil Josephson | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 4.51 per share. | 05 Jul 2022 | 1,525 | 11,039 (0%) | 0% | 4.5 | 6,878 | Common Shares |
| Kenneth Galbraith | Director, Chair, President & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jan 2022 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Neil Josephson | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 14.27 per share. | 07 Jan 2022 | 1,400 | 3,519 (0%) | 0% | 14.3 | 19,978 | Common Shares |
| Neil Josephson | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 14.28 per share. | 07 Jan 2022 | 3,600 | 7,119 (0%) | 0% | 14.3 | 51,408 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.00 per share. | 31 Aug 2021 | 4,900 | 36,333 (0%) | 0% | 15 | 73,500 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2021 | 4,900 | 77,600 | - | - | Stock Option (Right to Buy) | |
| Ali Tehrani | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 36.12 per share. | 12 Jul 2021 | 12,669 | 260,325 (0%) | 0% | 36.1 | 457,635 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. | 12 Jul 2021 | 12,669 | 272,994 (0%) | 0% | 4.3 | 54,555 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2021 | 12,669 | 44,991 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 29.49 per share. | 06 Jul 2021 | 299 | 10,770 (0%) | 0% | 29.5 | 8,818 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 29.49 per share. | 06 Jul 2021 | 454 | 31,433 (0%) | 0% | 29.5 | 13,388 | Common Shares |
| Kathryn ODriscoll | Chief People Officer | Grant, award, or other acquisition of securities at price $ 29.49 per share. | 06 Jul 2021 | 510 | 6,350 (0%) | 0% | 29.5 | 15,040 | Common Shares |
| James Priour | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 29.49 per share. | 06 Jul 2021 | 510 | 2,513 (0%) | 0% | 29.5 | 15,040 | Common Shares |
| Neil Josephson | Interim Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 29.49 per share. | 06 Jul 2021 | 461 | 2,054 (0%) | 0% | 29.5 | 13,595 | Common Shares |
| James Priour | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 2,266 | 2,953 (0%) | 0% | 0 | Common Shares | |
| James Priour | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 27.93 per share. | 13 Apr 2021 | 950 | 2,003 (0%) | 0% | 27.9 | 26,533 | Common Shares |
| James Priour | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2021 | 2,266 | 4,534 | - | - | Restricted Stock Unit | |
| Kathryn ODriscoll | Chief People Officer | Sale of securities on an exchange or to another person at price $ 34.72 per share. | 15 Mar 2021 | 786 | 5,003 (0%) | 0% | 34.7 | 27,290 | Common Shares |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2021 | 837 | 94,160 | - | - | Stock Option (Right to Buy) | |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.24 per share. | 15 Mar 2021 | 837 | 5,840 (0%) | 0% | 34.2 | 28,659 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 5,000 | - | - | Restricted Stock Unit | |
| Diana Hausman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.95 per share. | 10 Mar 2021 | 1,048 | 5,377 (0%) | 0% | 35.0 | 36,631 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 6,425 (0%) | 0% | 0 | Common Shares | |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 8,125 | 8,125 | - | - | Restricted Stock Unit | |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Ali Tehrani | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 150,000 | 150,000 | - | - | Stock Option (Right to Buy) | |
| Ali Tehrani | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 7,708 | 264,717 (0%) | 0% | 0 | Common Shares | |
| Ali Tehrani | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 34.95 per share. | 10 Mar 2021 | 4,392 | 260,325 (0%) | 0% | 35.0 | 153,516 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 7,708 | 15,417 | - | - | Restricted Stock Unit | |
| Ali Tehrani | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 25,000 | 25,000 | - | - | Restricted Stock Unit | |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 11,896 (0%) | 0% | 0 | Common Shares | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 8,125 | 8,125 | - | - | Restricted Stock Unit | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 5,000 | - | - | Restricted Stock Unit | |
| Neil Klompas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.95 per share. | 10 Mar 2021 | 1,425 | 10,471 (0%) | 0% | 35.0 | 49,809 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 8,125 | 8,125 | - | - | Restricted Stock Unit | |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 48,750 | 48,750 | - | - | Stock Option (Right to Buy) | |
| Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 5,000 | - | - | Restricted Stock Unit | |
| Anthony J. Polverino | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 34.95 per share. | 10 Mar 2021 | 1,048 | 30,979 (0%) | 0% | 35.0 | 36,631 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 2,500 | 32,027 (0%) | 0% | 0 | Common Shares | |
| Kathryn ODriscoll | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Kathryn ODriscoll | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 5,000 | 5,000 | - | - | Restricted Stock Unit | |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 1,354 | 2,709 | - | - | Restricted Stock Unit | |
| Kathryn ODriscoll | Chief People Officer | Sale of securities on an exchange or to another person at price $ 34.95 per share. | 10 Mar 2021 | 568 | 5,789 (0%) | 0% | 35.0 | 19,854 | Common Shares |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2021 | 1,354 | 6,357 (0%) | 0% | 0 | Common Shares | |
| James Priour | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 6,250 | 6,250 | - | - | Restricted Stock Unit | |
| James Priour | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2021 | 37,500 | 37,500 | - | - | Stock Option (Right to Buy) | |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.24 per share. | 12 Feb 2021 | 2,083 | 5,003 (0%) | 0% | 34.2 | 71,322 | Common Shares |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2021 | 2,083 | 94,997 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 30.92 per share. | 08 Jan 2021 | 284 | 9,396 (0%) | 0% | 30.9 | 8,781 | Common Shares |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 30.92 per share. | 07 Jan 2021 | 207 | 3,925 (0%) | 0% | 30.9 | 6,400 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 30.92 per share. | 07 Jan 2021 | 48 | 29,527 (0%) | 0% | 30.9 | 1,484 | Common Shares |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.19 per share. | 09 Dec 2020 | 8,380 | 17,502 (0%) | 0% | 4.2 | 35,150 | Common Shares |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2020 | 16,620 | 4,330 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2020 | 8,380 | 0 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 53.25 per share. | 09 Dec 2020 | 25,000 | 9,122 (0%) | 0% | 53.2 | 1,331,133 | Common Shares |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.67 per share. | 09 Dec 2020 | 16,620 | 34,122 (0%) | 0% | 5.7 | 94,249 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 56.16 per share. | 07 Dec 2020 | 850 | 55,511 (0%) | 0% | 56.2 | 47,736 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.84 per share. | 04 Dec 2020 | 3,182 | 9,750 (0%) | 0% | 11.8 | 37,675 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 3,182 | 47,673 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2020 | 2,850 | 68,028 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.12 per share. | 04 Dec 2020 | 6,032 | 3,718 (0%) | 0% | 55.1 | 332,476 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.82 per share. | 04 Dec 2020 | 2,850 | 6,568 (0%) | 0% | 9.8 | 27,987 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.84 per share. | 01 Dec 2020 | 14,145 | 21,985 (0%) | 0% | 11.8 | 167,477 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 574 | 50,281 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 127 | 70,751 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 14,145 | 50,855 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Dec 2020 | 4,122 | 70,878 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.01 per share. | 01 Dec 2020 | 701 | 3,718 (0%) | 0% | 55.0 | 38,563 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.84 per share. | 01 Dec 2020 | 574 | 4,419 (0%) | 0% | 11.8 | 6,796 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.82 per share. | 01 Dec 2020 | 127 | 3,845 (0%) | 0% | 9.8 | 1,247 | Common Shares |
| Diana Hausman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 55.19 per share. | 01 Dec 2020 | 18,267 | 3,718 (0%) | 0% | 55.2 | 1,008,240 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.82 per share. | 01 Dec 2020 | 4,122 | 7,840 (0%) | 0% | 9.8 | 40,478 | Common Shares |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2020 | 2,920 | 97,080 | - | - | Stock Option (Right to Buy) | |
| Kathryn ODriscoll | Chief People Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 34.24 per share. | 18 Nov 2020 | 2,920 | 2,920 (0%) | 0% | 34.2 | 99,981 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 39.04 per share. | 02 Nov 2020 | 3,500 | 56,361 (0%) | 0% | 39.0 | 136,624 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.84 per share. | 14 Sep 2020 | 10,000 | 43,718 (0%) | 0% | 11.8 | 118,400 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.74 per share. | 14 Sep 2020 | 10,000 | 13,718 (0%) | 0% | 15.7 | 157,400 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 17.15 per share. | 14 Sep 2020 | 10,000 | 23,718 (0%) | 0% | 17.2 | 171,500 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 9.82 per share. | 14 Sep 2020 | 10,000 | 33,718 (0%) | 0% | 9.8 | 98,200 | Common Shares |
| Diana Hausman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 45.00 per share. | 14 Sep 2020 | 40,000 | 3,718 (0%) | 0% | 45 | 1,800,000 | Common Shares |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 10,000 | 14,702 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 10,000 | 17,235 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 10,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2020 | 10,000 | 65,000 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 30.66 per share. | 02 Jul 2020 | 367 | 3,718 (0%) | 0% | 30.7 | 11,252 | Common Shares |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 30.66 per share. | 02 Jul 2020 | 277 | 9,112 (0%) | 0% | 30.7 | 8,493 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 30.66 per share. | 02 Jul 2020 | 488 | 29,479 (0%) | 0% | 30.7 | 14,962 | Common Shares |
| Hollings C. Renton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Lota S. Zoth | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Susan Mahony | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth J. Hillan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Natalie Sacks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Troy Cox | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2020 | 9,000 | 9,000 | - | - | Stock Option (Right to Buy) | |
| Ali Tehrani | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2020 | 1,000 | 57,660 | - | - | Stock Option (Right to Buy) | |
| Ali Tehrani | Director, Chief Executive Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.85 per share. | 13 Apr 2020 | 1,000 | 257,009 (0%) | 0% | 3.9 | 3,854 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 33.39 per share. | 03 Apr 2020 | 80 | 59,861 (0%) | 0% | 33.4 | 2,671 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Purchase of securities on an exchange or from another person at price $ 33.39 per share. | 03 Apr 2020 | 495 | 59,781 (0%) | 0% | 33.4 | 16,528 | Common Shares |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 7,500 | 7,500 | - | - | Restricted Stock Unit | |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Ali Tehrani | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 23,125 | 23,125 | - | - | Restricted Stock Unit | |
| Ali Tehrani | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 138,750 | 138,750 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 7,500 | 7,500 | - | - | Restricted Stock Unit | |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 7,500 | 7,500 | - | - | Restricted Stock Unit | |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
| Kathryn ODriscoll | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 4,063 | 4,063 | - | - | Restricted Stock Unit | |
| Kathryn ODriscoll | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2020 | 24,375 | 24,375 | - | - | Stock Option (Right to Buy) | |
| Troy Cox | Director | Purchase of securities on an exchange or from another person at price $ 46.50 per share. | 27 Jan 2020 | 7,500 | 7,500 (0%) | 0% | 46.5 | 348,750 | Common Shares |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 19.54 per share. | 08 Jan 2020 | 332 | 3,351 (0%) | 0% | 19.5 | 6,487 | Common Shares |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 19.54 per share. | 08 Jan 2020 | 394 | 8,835 (0%) | 0% | 19.5 | 7,699 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 19.54 per share. | 08 Jan 2020 | 371 | 28,991 (0%) | 0% | 19.5 | 7,249 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2019 | 27,500 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.00 per share. | 12 Dec 2019 | 27,500 | 28,620 (0%) | 0% | 15 | 412,500 | Common Shares |
| Kathryn ODriscoll | Chief People Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Nov 2019 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 12.49 per share. | 08 Jul 2019 | 520 | 3,019 (0%) | 0% | 12.5 | 6,495 | Common Shares |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.49 per share. | 08 Jul 2019 | 464 | 8,441 (0%) | 0% | 12.5 | 5,795 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 12.49 per share. | 08 Jul 2019 | 1,120 | 1,120 (0%) | 0% | 12.5 | 13,989 | Common Shares |
| Hollings C. Renton | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Lota S. Zoth | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Kenneth J. Hillan | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Natalie Sacks | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2019 | 6,704 | 0 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.25 per share. | 06 May 2019 | 1,604 | 7,977 (0%) | 0% | 19.3 | 30,878 | Common Stock |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.53 per share. | 06 May 2019 | 8,380 | 9,581 (0%) | 0% | 3.5 | 29,581 | Common Stock |
| Neil Klompas | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.22 per share. | 06 May 2019 | 6,704 | 1,201 (0%) | 0% | 19.2 | 128,855 | Common Stock |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.66 per share. | 06 May 2019 | 6,704 | 7,905 (0%) | 0% | 2.7 | 17,833 | Common Stock |
| Neil Klompas | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2019 | 8,380 | 0 | - | - | Stock Option (Right to Buy) | |
| Nick Bedford | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2019 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| David Kai Yuen Poon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.53 per share. | 06 May 2019 | 800 | 800 (0%) | 0% | 3.5 | 2,824 | Common Stock |
| David Kai Yuen Poon | See Remarks | Sale of securities on an exchange or to another person at price $ 19.20 per share. | 06 May 2019 | 800 | 0 (0%) | 0% | 19.2 | 15,360 | Common Stock |
| David Kai Yuen Poon | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 May 2019 | 800 | 3,390 | - | - | Stock Option (Right to Buy) | |
| Ali Tehrani | Director, Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 16.24 per share. | 29 Mar 2019 | 3,000 | 59,286 (0%) | 0% | 16.2 | 48,720 | Common Shares |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2019 | 15,000 | 15,000 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2019 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| Diana Hausman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 12.48 per share. | 08 Jan 2019 | 499 | 2,499 (0%) | 0% | 12.5 | 6,228 | Common Shares |
| Ali Tehrani | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2019 | 235,000 | 235,000 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2019 | 90,000 | 90,000 | - | - | Stock Option (Right to Buy) | |
| Neil Klompas | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 12.48 per share. | 08 Jan 2019 | 414 | 1,201 (0%) | 0% | 12.5 | 5,167 | Common Shares |
| Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2019 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
| David Kai Yuen Poon | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2019 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) |